113 results on '"Gangji, V."'
Search Results
2. Oleate Abrogates Palmitate-Induced Lipotoxicity and Proinflammatory Response in Human Bone Marrow-Derived Mesenchymal Stem Cells and Osteoblastic Cells
- Author
-
Gillet, C., Spruyt, D., Rigutto, S., Dalla Valle, A., Berlier, J., Louis, C., Debier, C., Gaspard, N., Malaisse, W. J., Gangji, V., and Rasschaert, J.
- Published
- 2015
3. P.07 - Ostéoblastes autologues (PREOB®) versus concentré de moelle autologue dans l’ostéonécrose de la tête fémorale au stade préfracturaire : étude randomisée
- Author
-
Hauzeur, J.P., Toungouz, M., Lechanteur, C., Beguin, Y., Baudoux, E., De Maertelaer, V., Pather, S., Katz, R., Ino, J., Egrise, D., Malaise, M., and Gangji, V.
- Published
- 2016
- Full Text
- View/download PDF
4. Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.
- Author
-
UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Sidiras, P, Spruyt, D, Gangji, V, Imbault, V, Sokolova, T, Durez, P, Communi, D, Rasschaert, J, Badot, V, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Sidiras, P, Spruyt, D, Gangji, V, Imbault, V, Sokolova, T, Durez, P, Communi, D, Rasschaert, J, and Badot, V
- Abstract
Anti-carbamylated protein antibodies (anti-CarP) are reported to be associated with increased disease activity and with more severe joint damage in rheumatoid arthritis (RA) patients. The present study investigated the presence of anti-CarP in various rheumatic diseases, and their specific clinical significance in RA, in Belgian rheumatology patients.: We tested sera from 254 RA patients, 56 healthy controls, and 153 patients with different rheumatic conditions: juvenile idiopathic arthritis (JIA), axial spondyloarthritis, systemic sclerosis, and Sjögren's syndrome (SS). An in-house enzyme-linked immunosorbent assay was used to detect immunoglobulin G antibodies against carbamylated foetal calf serum.: Anti-CarP were detected in 88 RA patients (34.6%), of whom 82% were also positive for anti-citrullinated protein antibodies (ACPAs) and 81% were also rheumatoid factor (RF) positive. Of note, 11 anti-CarP single-positive patients were detected (4.3%). The previously reported association with joint erosions was not detected. However, in ACPA- and RF-negative RA patients, the presence of anti-CarP was associated with higher disease activity and disability. Fifteen per cent of JIA patients and 30% of SS patients also tested positive for anti-CarP and their antibody levels did not differ significantly from those of anti-CarP-positive RA patients. Anti-CarP levels were, however, significantly higher in ACPA- or RF-positive patients.: Anti-CarP antibodies were detected in the sera of a cohort of Belgian RA patients. Moreover, they were also detected in primary SS patients and in JIA patients. In the seronegative subset of RA patients, anti-CarP antibodies showed prognostic value.
- Published
- 2021
5. Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases
- Author
-
Sidiras, P, primary, Spruyt, D, additional, Gangji, V, additional, Imbault, V, additional, Sokolova, T, additional, Durez, P, additional, Communi, D, additional, Rasschaert, J, additional, and Badot, V, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
- Author
-
Bergmann, P., Body, J.-J., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Reginster, J.-Y., and Gangji, V.
- Published
- 2009
7. Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.
- Author
-
Sidiras, P, Spruyt, D, Gangji, V, Imbault, V, Sokolova, T, Durez, P, Communi, D, Rasschaert, J, and Badot, V
- Subjects
RHEUMATOID arthritis ,RHEUMATISM ,DISEASE prevalence ,JUVENILE idiopathic arthritis ,DISEASE complications ,ENZYME-linked immunosorbent assay - Abstract
Objectives: Anti-carbamylated protein antibodies (anti-CarP) are reported to be associated with increased disease activity and with more severe joint damage in rheumatoid arthritis (RA) patients. The present study investigated the presence of anti-CarP in various rheumatic diseases, and their specific clinical significance in RA, in Belgian rheumatology patients. Method: We tested sera from 254 RA patients, 56 healthy controls, and 153 patients with different rheumatic conditions: juvenile idiopathic arthritis (JIA), axial spondyloarthritis, systemic sclerosis, and Sjögren's syndrome (SS). An in-house enzyme-linked immunosorbent assay was used to detect immunoglobulin G antibodies against carbamylated foetal calf serum. Results: Anti-CarP were detected in 88 RA patients (34.6%), of whom 82% were also positive for anti-citrullinated protein antibodies (ACPAs) and 81% were also rheumatoid factor (RF) positive. Of note, 11 anti-CarP single-positive patients were detected (4.3%). The previously reported association with joint erosions was not detected. However, in ACPA- and RF-negative RA patients, the presence of anti-CarP was associated with higher disease activity and disability. Fifteen per cent of JIA patients and 30% of SS patients also tested positive for anti-CarP and their antibody levels did not differ significantly from those of anti-CarP-positive RA patients. Anti-CarP levels were, however, significantly higher in ACPA- or RF-positive patients. Conclusion: Anti-CarP antibodies were detected in the sera of a cohort of Belgian RA patients. Moreover, they were also detected in primary SS patients and in JIA patients. In the seronegative subset of RA patients, anti-CarP antibodies showed prognostic value. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Course of juvenile rheumatoid arthritis: social life is less affected than school functioning, physical activity, and well-being during a follow-up of 1.5–13 years
- Author
-
Terrones-Munoz, V., Mélot, C., Gangji, V., Steinfeld, S., and Appelboom, Th.
- Published
- 2006
- Full Text
- View/download PDF
9. Analgesic Effect of Intravenous Pamidronate on Chronic Back Pain due to Osteoporotic Vertebral Fractures
- Author
-
Gangji, V. and Appelboom, T.
- Published
- 1999
- Full Text
- View/download PDF
10. Was the gastric ulcer due to cytomeg-alovirus?
- Author
-
Golstein, M., Appelboom, T., and Gangji, V.
- Published
- 1997
- Full Text
- View/download PDF
11. Intérêt des tests de force de préhension dans la polyarthrite rhumatoïde
- Author
-
Robert, C., primary, Mahéo, S., additional, Bode Blanco, S., additional, Lepers, L., additional, Brassine, E., additional, Gangji, V., additional, and Badot, V., additional
- Published
- 2017
- Full Text
- View/download PDF
12. Ostéoblastes autologues (PREOB®) versus concentré de moelle autologue dans l’ostéonécrose de la tête fémorale au stade préfracturaire: étude randomisée
- Author
-
Hauzeur, J.P., primary, Toungouz, M., additional, Lechanteur, C., additional, Beguin, Y., additional, Baudoux, E., additional, De Maertelaer, V., additional, Pather, S., additional, Katz, R., additional, Ino, J., additional, Egrise, D., additional, Malaise, M., additional, and Gangji, V., additional
- Published
- 2016
- Full Text
- View/download PDF
13. THU0540 Autologous Osteoblastic Cells versus Concentrated Bone Marrow Implantation in Osteonecrosis of The Femoral Head: A Randomized Controlled Single Blind Study
- Author
-
Gangji, V., primary, Toungouz, M., additional, Lechanteur, C., additional, Beguin, Y., additional, Baudoux, E., additional, De maertelaer, V., additional, Pather, S., additional, Katz, R., additional, Ino, J., additional, Egrise, D., additional, Malaise, M., additional, and Hauzeur, J.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
14. Oleate abrogates palmitate-induced lipotoxicity andpro-inflammatory response in human bone marrowderivemesenchymal stem cells and osteoblastic cells
- Author
-
UCL - SST/ISV - Institut des sciences de la vie, Gillet, C., Spruyt, D., Rigutto, Simon, Dalla Valle, Alessio, Berlier, J., Louis, Caroline, Debier, Cathy, Gaspard, N., Malaisse, W.J., Gangji, V., Rasschaert, J., UCL - SST/ISV - Institut des sciences de la vie, Gillet, C., Spruyt, D., Rigutto, Simon, Dalla Valle, Alessio, Berlier, J., Louis, Caroline, Debier, Cathy, Gaspard, N., Malaisse, W.J., Gangji, V., and Rasschaert, J.
- Abstract
Osteoporosis is a metabolic bone disease associated with unequilibrated bone remodeling resulting from decreased bone formation and/or increased bone resorption, leading to progressive bone loss. In osteoporotic patients, low bone mass is associated with an increase of bone marrow fat resulting from accumulation of adipocytes within bone marrow (BM). BM adipocytes are active secretory cells, releasing cytokines, adipokines and free fatty acids (FA) that influence the BM microenvironment and altered the biology of neighboring cells. Therefore, we examined the influence of palmitate and oleate, two highly prevalent FA in human organism and diet, on the function and survival of human mesenchymal stem cells (MSC) and MSC-derived osteoblastic cells. The saturated FA palmitate exerted a cytotoxic action via initiation of endoplasmic reticulum stress and activation of the NF-B and ERK pathways. In addition, palmitate induced a pro-inflammatory response, as determined by the upregulation of TLR4 expression as well as the increase of IL-6 and IL-8 expression and secretion. Moreover,weshowed that MSC-derived osteoblastic cells were more sensitive to lipotoxicity than undifferentiated MSC. The monounsaturated FA oleate fully neutralized palmitate-induced lipotoxicity by impairing activation of the pathways triggered by the saturated FA. Moreover, oleate promoted palmitate detoxification by fostering its esterification into triglycerides and storage in lipid droplets. Altogether, our data showed that physiological concentrations of palmitate and oleate differently modulated cell death and function in bone cells. We therefore propose that FA could influence skeletal health.
- Published
- 2015
15. Cryofibrinogen levels are increased in non-traumatic osteonecrosis: a new pathogenic clue to osteonecrosis?
- Author
-
Soyfoo, M. S., primary, Watik, A., additional, Stordeur, P., additional, and Gangji, V., additional
- Published
- 2013
- Full Text
- View/download PDF
16. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome
- Author
-
Dupire, G, primary, Nicaise, C, additional, Gangji, V, additional, and Soyfoo, MS, additional
- Published
- 2012
- Full Text
- View/download PDF
17. Greffe de moelle autologue dans l'ostéonécrose aseptique de la tête fémorale: résultats à cinq ans d'une étude controlée et en aveugle
- Author
-
Hauzeur, J.P., primary and Gangji, V., additional
- Published
- 2007
- Full Text
- View/download PDF
18. Treatment of osteonecrosis of the femoral head with implantation of preosteoblastic cells into the necrotic zone: Case report
- Author
-
Gangji, V., primary, Bastianelli, E., additional, Toungouz, M., additional, and Hauzeur, J., additional
- Published
- 2007
- Full Text
- View/download PDF
19. Use of total body MRI for the diagnosis of multifocal ON lesions: Case report
- Author
-
Biltiau, N., primary, Gillard, B., additional, Bastianelli, E., additional, and Gangji, V., additional
- Published
- 2007
- Full Text
- View/download PDF
20. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells: Five-year follow-up
- Author
-
Gangji, V., primary, Toungouz, M., additional, Lambermont, M., additional, Bastianelli, E., additional, and Hauzeur, J., additional
- Published
- 2007
- Full Text
- View/download PDF
21. Séquence d'apparition des lésions d'ostéonécrose multifocale
- Author
-
Biltiau, N., primary, Stallenberg, B., additional, Brasseur, C., additional, Gillard, B., additional, Tant, L., additional, Steinfeld, S., additional, Margaux, J., additional, Appelboom, T., additional, Hauzeur, J.P., additional, and Gangji, V., additional
- Published
- 2006
- Full Text
- View/download PDF
22. OP0066 Effects of tnf blockade with infliximab in patients with primary sjÖgren’s syndrome: an open pilot study
- Author
-
Steinfeld, SD, primary, Demols, P, additional, Gangji, V, additional, and Appelboom, T, additional
- Published
- 2001
- Full Text
- View/download PDF
23. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts.
- Author
-
Gazzerro, E, primary, Gangji, V, additional, and Canalis, E, additional
- Published
- 1998
- Full Text
- View/download PDF
24. Calretinin is Transiently Expressed in Tendon Fibroblasts of the Paravertebral Region of the Chick Embryo
- Author
-
Gangji, V, primary, Krebs, C, additional, Rooze, M, additional, and Pochet, R, additional
- Published
- 1997
- Full Text
- View/download PDF
25. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique.
- Author
-
Gangji V, Hauzeur J, Gangji, Valérie, and Hauzeur, Jean-Philippe
- Abstract
Background: Aseptic nontraumatic osteonecrosis of the femoral head is a disorder that can lead to femoral head collapse and the need for total hip replacement. Since osteonecrosis may be a disease of mesenchymal cells or bone cells, the possibility has been raised that bone marrow containing osteogenic precursors implanted into a necrotic lesion of the femoral head may be of benefit in the treatment of this condition. For this reason, we studied the implantation of autologous bone-marrow mononuclear cells in a necrotic lesion of the femoral head to determine the effect on the clinical symptoms and the stage and volume of osteonecrosis.Methods: We studied thirteen patients (eighteen hips) with stage-I or II osteonecrosis of the femoral head, according to the system of the Association Research Circulation Osseous. The hips were allocated to a program of either core decompression (the control group) or core decompression and implantation of autologous bone-marrow mononuclear cells (the bone-marrow-graft group). Both patients and assessors were blind with respect to treatment-group assignment. The primary outcomes studied were safety, clinical symptoms, and disease progression.Results: After twenty-four months, there was a significant reduction in pain (p = 0.021) and in joint symptoms measured with the Lequesne index (p = 0.001) and the WOMAC index (p = 0.013) within the bone-marrow-graft group. At twenty-four months, five of the eight hips in the control group had deteriorated to stage III, whereas only one of the ten hips in the bone-marrow-graft group had progressed to this stage. Survival analysis showed a significant difference in the time to collapse between the two groups (p = 0.016). Implantation of bone-marrow mononuclear cells was associated with only minor side effects.Conclusions: Implantation of autologous bone-marrow mononuclear cells appears to be a safe and effective treatment for early stages of osteonecrosis of the femoral head. Although the findings of this study are promising, their interpretation is limited because of the small number of patients and the short duration of follow-up. Further study is needed to confirm the results. [ABSTRACT FROM AUTHOR]- Published
- 2005
26. Cerebellar spongiform degeneration induced by acute lithium intoxication in the rat
- Author
-
Dethy, S., Manto, M., Bastianelli, E., Gangji, V., Laute, M. A., Goldman, S., and Hildebrand, J.
- Published
- 1997
- Full Text
- View/download PDF
27. Successful treatment of SAPHO syndrome with ibandronate.
- Author
-
Soyfoo MS, Gangji V, Margaux J, Soyfoo, Muhammad S, Gangji, Valérie, and Margaux, Joelle
- Published
- 2010
- Full Text
- View/download PDF
28. Early Kienböck disease cannot be detected by radiography: Comment on the clinical image by Ko et al.
- Author
-
Hauzeur JP and Gangji V
- Published
- 2010
- Full Text
- View/download PDF
29. Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial.
- Author
-
Jayankura M, Thomas T, Seefried L, Dubrana F, Günther KP, Rondia J, Davis ET, Winnock de Grave P, Carron P, Gangji V, Vande Berg B, Godeaux O, and Sonnet W
- Subjects
- Adult, Male, Humans, Female, Treatment Outcome, Decompression, Surgical adverse effects, Decompression, Surgical methods, Double-Blind Method, Femur Head surgery, Femur Head Necrosis diagnostic imaging, Femur Head Necrosis surgery
- Abstract
Background: Osteonecrosis of the femoral head (ONFH) is a disabling disease that can ultimately progress to collapse of the femoral head, often resulting in THA. Core decompression of the femoral head combined with cell therapies have shown beneficial effects in previous clinical studies in patients with early-stage (Association Research Circulation Osseous [ARCO] Stage I and II) ONFH. However, high-quality evidence confirming the efficacy of this treatment modality is still lacking., Questions/purposes: (1) Is core decompression combined with autologous osteoblastic cell transplantation superior to core decompression with placebo implantation in relieving disease-associated pain and preventing radiologic ONFH progression in patients with nontraumatic early-stage ONFH? (2) What adverse events occurred in the treatment and control groups?, Methods: This study was a Phase III, multicenter, randomized, double-blind, controlled study conducted from 2011 to 2019 (ClinicalTrails.gov registry number: NCT01529008). Adult patients with ARCO Stage I and II ONFH were randomized (1:1) to receive either core decompression with osteoblastic cell transplantation (5 mL with 20 x 10 6 cells/mL in the study group) or core decompression with placebo (5 mL of solution without cells in the control group) implantation. Thirty percent (68 of 230) of the screened patients were eligible for inclusion in the study; of these, 94% (64 of 68) underwent a bone marrow harvest or sham procedure (extended safety set) and 79% (54 of 68) were treated (study group: 25 patients; control group: 29). Forty-nine patients were included in the efficacy analyses. Similar proportions of patients in each group completed the study at 24 months of follow-up (study group: 44% [11 of 25]; control: 41% [12 of 29]). The study and control groups were comparable in important ways; for example, in the study and control groups, most patients were men (79% [27 of 34] and 87% [26 of 30], respectively) and had ARCO Stage II ONFH (76% [19 of 25] and 83% [24 of 29], respectively); the mean age was 46 and 45 years in the study and control groups, respectively. The follow-up period was 24 months post-treatment. The primary efficacy endpoint was the composite treatment response at 24 months, comprising the clinical response (clinically important improvement in pain from baseline using the WOMAC VA3.1 pain subscale, defined as 10 mm on a 100-mm scale) and radiologic response (the absence of progression to fracture stage [≥ ARCO Stage III], as assessed by conventional radiography and MRI of the hips). Secondary efficacy endpoints included the percentages of patients achieving a composite treatment response, clinical response, and radiologic response at 12 months, and the percentage of patients undergoing THA at 24 months. We maintained a continuous reporting system for adverse events and serious adverse events related to the study treatment, bone marrow aspiration and sham procedure, or other study procedures throughout the study. A planned, unblinded interim analysis of efficacy and adverse events was completed at 12 months. The study was discontinued because our data safety monitoring board recommended terminating the study for futility based on preselected futility stopping rules: conditional power below 0.20 and p = 0.01 to detect an effect size of 10 mm on the 100-mm WOMAC VA3.1 pain subscale (improvement in pain) and the absence of progression to fracture (≥ ARCO Stage III) observed on radiologic assessment, reflecting the unlikelihood that statistically beneficial results would be reached at 24 months after the treatment., Results: There was no difference between the study and control groups in the proportion of patients who achieved a composite treatment response at 24 months (61% [14 of 23] versus 69% [18 of 26]; p = 0.54). There was no difference in the proportion of patients with a treatment response at 12 months between the study and control groups (14 of 21 versus 15 of 23; p = 0.92), clinical response (17 of 21 versus 16 of 23; p = 0.38), and radiologic response (16 of 21 versus 18 of 23; p = 0.87). With the numbers available, at 24 months, there was no difference in the proportion of patients who underwent THA between the study and control groups (24% [six of 25] versus 14% [four of 29]). There were no serious adverse events related to the study treatment, and only one serious adverse event (procedural pain in the study group) was related to bone marrow aspiration. Nonserious adverse events related to the treatment were rare in the study and control groups (4% [one of 25] versus 14% [four of 29]). Nonserious adverse events related to bone marrow or sham aspiration were reported by 15% (five of 34) of patients in the study group and 7% (two of 30) of patients in the control group., Conclusion: Our study did not show any advantage of autologous osteoblastic cells to improve the results of core decompression in early-stage (precollapse) ONFH. Adverse events related to treatment were rare and generally mild in both groups, although there might have been a potential risk associated with cell expansion. Based on our findings, we do not recommend the combination of osteoblastic cells and core decompression in patients with early-stage ONFH. Further, well-designed studies should be conducted to explore whether other treatment modalities involving a biological approach could improve the overall results of core decompression., Level of Evidence: Level II, therapeutic study., Competing Interests: All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request., (Copyright © 2023 by the Association of Bone and Joint Surgeons.)
- Published
- 2023
- Full Text
- View/download PDF
30. Collapse-related bone changes at multidetector CT in ARCO 1-2 osteonecrotic femoral heads: correlation with clinical and MRI data.
- Author
-
Mourad CJ, Libert F, Gangji V, Michoux N, and Vande Berg BC
- Subjects
- Humans, Femur Head pathology, Prospective Studies, Magnetic Resonance Imaging methods, Multidetector Computed Tomography, Retrospective Studies, Pain, Femur Head Necrosis diagnostic imaging, Femur Head Necrosis complications, Femur Head Necrosis pathology
- Abstract
Objective: To assess the frequency of collapse-related bone changes at multi-detector CT (MDCT) in osteonecrotic femoral heads (ONFH) and to compare clinical parameters and MRI findings in Association Research Circulation Osseous (ARCO) 1-2 ONFH with or without collapse-related bone changes (CRBC) at MDCT., Materials and Methods: This is a secondary analysis of radiographic, MRI, and MDCT examinations of ONFH of patients eligible for a prospective clinical trial. Radiographs and MRI were analyzed to perform ARCO staging. Frequency of CRBC at MDCT including cortical interruption, trabecular interruption, impaction, and resorption was determined by two readers (R1, R2) blinded to radiographic, MRI, and clinical data. Baseline clinical and imaging data of ARCO 1-2 ONFH were compared between hips with or without CRBC at MDCT., Results: One hundred thirty-two hips of 77 participants were analyzed. There were 78 non-collapsed and 54 collapsed ONFH. For R1 and R2, 31/78 (40%) and 20/78 (26%) ARCO 1-2 ONFH and 54/54 (100%) and 53/54 (98%) ARCO 3-4 ONFH showed at least one CRBC at MDCT. For both readers, there was no significant difference in pain, functional impairment, size of lesion, and the presence of BME on MRI between ARCO 1-2 hips with or without CRBC at MDCT., Conclusion: Twenty-six to forty percent of ARCO 1-2 ONFH demonstrate at least one collapse-related bone change at CT. Their clinical and MRI findings do not differ from those without collapse-related bone changes., Key Points: • Ninety-eight to one hundred percent of collapsed and 26-40% of non-collapsed osteonecrotic femoral heads presented at least one collapse-related bone change at CT (cortical or trabecular bone interruption, trabecular bone impaction, or resorption). • There was no significant difference in age, sex, pain, functional impairment, size of lesion, or frequency of marrow edema on MRI between non-collapsed hips with or without collapse-related bone changes at CT. • The significance of collapse-related bone changes at CT should be further assessed., (© 2022. The Author(s), under exclusive licence to European Society of Radiology.)
- Published
- 2023
- Full Text
- View/download PDF
31. Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis.
- Author
-
Sidiras P, Lechanteur J, Imbault V, Sokolova T, Durez P, Gangji V, Communi D, and Rasschaert J
- Subjects
- Autoantibodies, Biomarkers, Humans, Peptides, Cyclic, Proteins, Proteomics, Arthritis, Rheumatoid diagnosis, Autoantigens, Hemopexin, Pregnancy-Associated alpha 2-Macroglobulins
- Abstract
Objectives: Anti-carbamylated protein antibodies (anti-CarPAs) are present in RA sera and have been associated with erosive disease. The exact targets of anti-CarPAs in vivo are currently not well known; we used a proteomic approach on serum and SF of RA patients to assess the human carbamylome and to identify carbamylated autoantigens as potential biomarkers in early RA., Methods: Mass spectrometry was performed on SF and serum from RA patients. Carbamylated proteins present in both sample types were selected as candidate autoantigens for the establishment of ELISAs. A cohort of early RA patients was tested for positivity for specific anti-CarPAs., Results: Eleven novel carbamylated proteins were identified, and five were selected as potential autoantigens for detection of anti-CarPAs. Among them, antibodies against carbamylated hemopexin (anti-CaHPX) and alpha-2-macroglobulin (anti-CaA2M) showed comparable diagnostic value to the established carbamylated foetal calf serum-based ELISA. A cohort of 189 early RA patients was studied. The combination of these new biomarkers with anti-citrullinated protein antibodies and RF identified 89% of early RA patients in our cohort. There was little correlation between the tested biomarkers, and each one of the tested antigens could identify a different subset of seronegative RA patients. Anti-CaA2M positivity showed clinical potential, being associated with higher disease disability., Conclusion: We highlight the detection of novel carbamylated autoantigens in vivo using a combined proteomics approach in the SF and serum of RA patients. Anti-CaHPX and anti-CaA2M are promising clinical biomarkers, especially in seronegative RA., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2022
- Full Text
- View/download PDF
32. The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head.
- Author
-
Yoon BH, Mont MA, Koo KH, Chen CH, Cheng EY, Cui Q, Drescher W, Gangji V, Goodman SB, Ha YC, Hernigou P, Hungerford MW, Iorio R, Jo WL, Jones LC, Khanduja V, Kim HKW, Kim SY, Kim TY, Lee HY, Lee MS, Lee YK, Lee YJ, Nakamura J, Parvizi J, Sakai T, Sugano N, Takao M, Yamamoto T, and Zhao DW
- Subjects
- Humans, Magnetic Resonance Imaging, Radiography, Tomography, X-Ray Computed, Femur Head diagnostic imaging, Femur Head Necrosis diagnostic imaging
- Abstract
Background: The Association Research Circulation Osseous (ARCO) presents the 2019 revised staging system of osteonecrosis of the femoral head (ONFH) based on the 1994 ARCO classification., Methods: In October 2018, ARCO established a task force to revise the staging system of ONFH. The task force involved 29 experts who used a web-based survey for international collaboration. Content validity ratios for each answer were calculated to identify the levels of agreement. For the rating queries, a consensus was defined when more than 70% of the panel members scored a 4 or 5 rating on a 5-point scale., Results: Response rates were 93.1%-100%, and through the 4-round Delphi study, the 1994 ARCO classification for ONFH was successfully revised. The final consensus resulted in the following 4-staged system: stage I-X-ray is normal, but either magnetic resonance imaging or bone scan is positive; stage II-X-ray is abnormal (subtle signs of osteosclerosis, focal osteoporosis, or cystic change in the femoral head) but without any evidence of subchondral fracture, fracture in the necrotic portion, or flattening of the femoral head; stage III-fracture in the subchondral or necrotic zone as seen on X-ray or computed tomography scans. This stage is further divided into stage IIIA (early, femoral head depression ≤2 mm) and stage IIIB (late, femoral head depression >2 mm); and stage IV-X-ray evidence of osteoarthritis with accompanying joint space narrowing, acetabular changes, and/or joint destruction. This revised staging system does not incorporate the previous subclassification or quantitation parameters, but the panels agreed on the future development of a separate grading system for predicting disease progression., Conclusion: A staging system has been developed to revise the 1994 ARCO classification for ONFH by an expert panel-based Delphi survey. ARCO approved and recommends this revised system as a universal staging of ONFH., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
33. Induction of Stearoyl-CoA 9-Desaturase 1 Protects Human Mesenchymal Stromal Cells Against Palmitic Acid-Induced Lipotoxicity and Inflammation.
- Author
-
Dalla Valle A, Vertongen P, Spruyt D, Lechanteur J, Suain V, Gaspard N, Brion JP, Gangji V, and Rasschaert J
- Abstract
In bone diseases such as osteonecrosis and osteoporosis, a shift toward a preferential differentiation of mesenchymal stromal cells (MSC) into adipocytes at the expense of the osteoblastic lineage is described, leading to excessive accumulation of adipocytes in the bone marrow of the patients. The influence of cytokines and adipokines secreted by adipocytes on skeletal health is already well-documented but the impact of free fatty acids release on bone cell biology and viability is an emerging concept. We have previously demonstrated that the saturated fatty acid (SFA) palmitate (Palm) is cytotoxic for human MSC (hMSC) and osteoblasts whereas oleate (Ole), a monounsaturated fatty acid (MUFA), has no toxic effect. Moreover, Ole protects cells against lipotoxicity. Our observations led us to propose that the toxicity of the SFA is not correlated to its intracellular accumulation but could rather be related to the intracellular SFA/MUFA ratio, which finally determines the toxic effect of SFA. Therefore, in the present study, we have investigated the potential protective role of the enzyme stearoyl-CoA 9-desaturase 1 (SCD1) against the deleterious effects of Palm. SCD1 is an enzyme responsible for desaturation of SFA to MUFA; its activation could therefore lead to modifications of the intracellular SFA/MUFA ratio. In the present study, we showed that hMSC express SCD1 and liver X receptors (LXRs), transcription factors regulating SCD1 expression. Human MSC treatment with a LXRs agonist triggered SCD1 expression and drastically reduced Palm-induced cell mortality, caspases 3/7 activation, endoplasmic reticulum stress and inflammation. We also observed that, in the presence of Palm, the LXRs agonist provoked lipid droplets formation, augmented the total cellular neutral lipid content but decreased the SFA/MUFA ratio when compared to Palm treatment alone. Addition of an inhibitor of SCD1 activity abrogated the positive effects of the LXRs agonist, suggesting that SCD1 could play a key role in protecting hMSC against lipotoxicity., (Copyright © 2019 Dalla Valle, Vertongen, Spruyt, Lechanteur, Suain, Gaspard, Brion, Gangji and Rasschaert.)
- Published
- 2019
- Full Text
- View/download PDF
34. Etiologic Classification Criteria of ARCO on Femoral Head Osteonecrosis Part 1: Glucocorticoid-Associated Osteonecrosis.
- Author
-
Yoon BH, Jones LC, Chen CH, Cheng EY, Cui Q, Drescher W, Fukushima W, Gangji V, Goodman SB, Ha YC, Hernigou P, Hungerford M, Iorio R, Jo WL, Khanduja V, Kim H, Kim SY, Kim TY, Lee HY, Lee MS, Lee YK, Lee YJ, Mont MA, Sakai T, Sugano N, Takao M, Yamamoto T, and Koo KH
- Subjects
- Advisory Committees, Consensus, Delphi Technique, Femur Head Necrosis etiology, Humans, Internationality, Prednisolone adverse effects, Risk Factors, Femur Head Necrosis chemically induced, Femur Head Necrosis classification, Glucocorticoids adverse effects
- Abstract
Background: Glucocorticoid usage, a leading cause of osteonecrosis of the femoral head (ONFH), and its prevalence was reported in 25%-50% of non-traumatic ONFH patients. Nevertheless, there have been no unified criteria to classify glucocorticoid-associated ONFH (GA-ONFH). In 2015, the Association Research Circulation Osseous addressed the issue of developing a classification scheme., Methods: In June 2017, a task force was set up to conduct a Delphi survey concerning ONFH. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey consists of questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, the panel reached a consensus on the classification criteria. The response rates were 100% (Round 1), 96% (Round 2), and 100% (Round 3), respectively., Results: The consensus on the classification criteria of GA-ONFH included the following: (1) patients should have a history of glucocorticoid use >2 g of prednisolone or its equivalent within a 3-month period; (2) osteonecrosis should be diagnosed within 2 years after glucocorticoid usage, and (3) patients should not have other risk factor(s) besides glucocorticoids., Conclusion: Association Research Circulation Osseous established classification criteria to standardize clinical studies concerning GA-ONFH., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
35. Etiologic Classification Criteria of ARCO on Femoral Head Osteonecrosis Part 2: Alcohol-Associated Osteonecrosis.
- Author
-
Yoon BH, Jones LC, Chen CH, Cheng EY, Cui Q, Drescher W, Fukushima W, Gangji V, Goodman SB, Ha YC, Hernigou P, Hungerford M, Iorio R, Jo WL, Khanduja V, Kim H, Kim SY, Kim TY, Lee HY, Lee MS, Lee YK, Lee YJ, Mont MA, Sakai T, Sugano N, Takao M, Yamamoto T, and Koo KH
- Subjects
- Advisory Committees, Consensus, Delphi Technique, Femur Head Necrosis chemically induced, Humans, Internationality, Risk Factors, Alcohol Drinking adverse effects, Ethanol adverse effects, Femur Head Necrosis classification, Femur Head Necrosis etiology
- Abstract
Background: Although alcohol is a leading risk factor for osteonecrosis of the femoral head (ONFH) and its prevalence reportedly ranges from 20% to 45%, there are no unified classification criteria for this subpopulation. In 2015, Association Research Circulation Osseous decided to develop classification criteria for alcohol-associated ONFH., Methods: In June of 2017, Association Research Circulation Osseous formed a task force to conduct a Delphi survey. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey included questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, consensus was reached on the classification criteria. The response rates for the 3 Delphi rounds were 100% (round 1), 96% (round 2), and 100% (round 3)., Results: The consensus on the classification criteria of alcohol-associated ONFH included the following: (1) patients should have a history of alcohol intake >400 mL/wk (320 g/wk, any type of alcoholic beverage) of pure ethanol for more than 6 months; (2) ONFH should be diagnosed within 1 year after alcohol intake of this dose; and (3) patients should not have other risk factor(s)., Conclusion: ARCO-established classification criteria to standardize clinical studies concerning AA-ONFH., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
36. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial.
- Author
-
Hauzeur JP, De Maertelaer V, Baudoux E, Malaise M, Beguin Y, and Gangji V
- Subjects
- Adult, Arthroplasty, Replacement, Hip statistics & numerical data, Bone Marrow Transplantation adverse effects, Disease Progression, Double-Blind Method, Female, Femur Head surgery, Follow-Up Studies, Hip Joint surgery, Humans, Male, Middle Aged, Pain Measurement, Prognosis, Transplantation, Autologous methods, Treatment Outcome, Bone Marrow Transplantation methods, Decompression, Surgical methods, Femur Head Necrosis surgery
- Abstract
Purpose: The fracture stage of non-traumatic osteonecrosis (ON stage 3) of the femoral head (ONFH) has an unfavourable prognosis frequently requiring total hip replacement (THR). The percentage could be lowered after core decompression. In earlier non-fracture ON stages, implantation of autologous bone marrow aspirate concentrate (BMAC) improved the effect of core decompression. The purpose was to evaluate the effect of BMAC in addition to core decompression in stage 3 ONFH., Methods: A double blind RCT was conducted comparing two groups: core decompression plus saline injection or core decompression plus BMAC implantation. Both patients and assessors were blinded to the treatment assignments. Evaluations were done at baseline, three, six, 12, and 24 months, including pain (VAS), WOMAC, side-effects, radiological evolution including ARCO subclassifications, together with possible THR requirement. The primary endpoint was the need for THR. The second endpoints included the clinical symptoms such as pain and functional ability and the progression of the ON lesions as well as the appearance of osteoarthritis features (ARCO stage 4). Both groups included 23 hips (19 patients)., Results: No differences were found between the groups for THR requirements, clinical tests, and radiological evolution. In both groups, 15/23 hips needed THR. The radiological evolution of the ONFH lesions in term of location, extension, surface collapse, and dome depression was moderate in both groups and was not correlated with the need of THR., Conclusions: Implantation of BMAC after core decompression did not produce any improvement of the evolution of ONFH stage 3. Level of evidence I.
- Published
- 2018
- Full Text
- View/download PDF
37. Non traumatic osteonecrosis of the femoral head is associated with low bone mass.
- Author
-
Gangji V, Soyfoo MS, Heuschling A, Afzali V, Moreno-Reyes R, Rasschaert J, Gillet C, Fils JF, and Hauzeur JP
- Subjects
- Aged, Bone Diseases, Metabolic epidemiology, Female, Humans, Male, Middle Aged, Prevalence, Risk Factors, Bone Density, Femur Head Necrosis etiology, Osteoporosis epidemiology
- Abstract
Objective: Osteoporosis (OP) and osteonecrosis of the femoral head (ONFH) share common clinical and pathophysiological features we sought to determine whether ONFH was associated with an increased prevalence of OP and whether the increased prevalence of OP was related to the stage of ONFH at diagnosis., Methods: We included 243 patients with ONFH and 399 age and sex-matched healthy controls. Data was gathered including demography, risk factors, ARCO staging of ONFH and bone mineral density (BMD)., Results: Overall, BMD (defined by the T-score) was significantly lower in the ONFH group at both the femoral head (-0.96±1.11) and the lumbar spine (-1.22±1.47) compared to the control group (-0.55±0.97 and -0.73±1.31) (p<0.01). The ONFH group depicted a significantly higher proportion of osteopenia (50.39% vs 40.87%, p=0.027) and of OP (18.78% vs 7.33%, p<0.001) relative to the control group. Stage 1 and 2 ONFH patients (53.86%, p=0.0203; OR=1.54 (95% CI: [1.04; 2.29])) were at a higher risk of osteopenia than the control group (40.88%), but not stages 3 or 4 (48.47%, p=0.2569; OR=1.27 (95% CI: [0.78; 2.06]). Patients with stage 3 or 4 ONFH (25.31%, p<0.001; OR=3.93 (95% CI: [1.63; 10.96])) were at a higher risk of osteoporosis than patients in the stage 1 and 2 ONFH (7.24%), and compared to the control group (7.33%, adj. p-value<0.001; OR=4.89 (95% CI: [2.77; 8.76])., Conclusions: Non-traumatic osteonecrosis of the femoral heads is associated with low bone mineral density. This study showed that fractural stages ONFH were associated with a 5-fold risk of osteoporosis., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
38. Value of non-identified ANCA (non-PR3, non-MPO) in the diagnosis of granulomatosis with polyangiitis (Wegener's granulomatosis).
- Author
-
Givaudan M, Vandergheynst F, Stordeur P, Ocmant A, Melot C, Gangji V, and Soyfoo MS
- Subjects
- Adult, Diagnosis, Differential, Female, Granulomatosis with Polyangiitis immunology, Humans, Male, Middle Aged, Retrospective Studies, Antibodies, Antineutrophil Cytoplasmic, Granulomatosis with Polyangiitis diagnosis
- Abstract
Objective: Determine the frequency of granulomatosis with polyangiitis (GPA) associated with non-identified ANCA (non-MPO, non-PR3 ANCA) and secondarily compare their clinic with GPA associated with MPO-positive or PR3-positive ANCA., Methods: In a monocentric retrospective observational study, clinical data of 398 patients with non-identified ANCA (titer of ANCA at least 1/80 by immunofluorescence on ethanol fixed PMN) was gathered over a period of 6 years. GPA patients from this population were compared with GPA patients with identified ANCA on the basis of clinical, biological, immunological and histological features., Results: The most common diseases associated with non-identified ANCA were inflammatory bowel diseases accounting for 17% of diseases. GPA accounted for only 1.8% of cases. There were no significant differences in terms of clinical and histological characteristics between GPA with non-identified ANCA and GPA with identified ANCA, but significantly higher CRP levels were observed in GPA patients with identified ANCA (p = 0.005). Localized disease (ear, nose and throat and/or lung involvement without any other systemic involvement) was more frequent in the group of GPA with nonidentified ANCA (p = 0.047) as compared to GPA with identified ANCA. This explains that the former group of patients was less frequently treated by cyclophosphamide than the latter (p = 0.016)., Conclusion: GPA with non-MPO, non-PR3 ANCAs is relatively rare. Our study suggests that GPA with nonidentified ANCA differs from GPA with identified ANCA by the frequency of localized forms.
- Published
- 2017
- Full Text
- View/download PDF
39. High Prevalence of Undiagnosed Axial Spondyloarthritis in Patients with Chronic Low Back Pain Consulting Non-Rheumatologist Specialists in Belgium: SUSPECT Study.
- Author
-
Tant L, Delmotte N, Van den Enden M, Gangji V, and Mielants H
- Abstract
Introduction: Diagnosis of axial spondyloarthritis (SpA) can be delayed for several years mainly because of low awareness of axial SpA among non-rheumatologists who are the first interlocutors of potential SpA patients. One strategy to decrease the delay between appearance of first symptoms and diagnosis of axial SpA and to allow early management of the disease is to provide the non-rheumatologists with tools to identify patients requiring prompt referral to rheumatologists. This study was designed to evaluate in a real-world setting whether screening patients with chronic low back pain who consult physical medicine and rehabilitation (PMR) physicians, orthopedists, and ophthalmologists is useful in detecting axial SpA., Methods: During this non-interventional cross-sectional study, data from 161 patients with chronic back pain, consulting an orthopedist, PMR physician, or ophthalmologist were collected during a single visit. Any patient who presented with at least four out of five symptoms of inflammatory back pain (IBP) and at least one additional SpA feature were to be referred to a rheumatologist. Analysis was purely descriptive., Results: IBP was diagnosed in approximately half of the patients (89 patients) and 72 of them met the referral criteria. A total of 117 patients were finally referred to a rheumatologist and axial SpA was diagnosed for 37 of them., Conclusions: The high prevalence of undiagnosed axial SpA in patients with chronic back pain visiting PMR physicians, orthopedists, and ophthalmologists suggests that these healthcare professionals may play a key role in the strategy developed to shorten the delay observed in the formal diagnosis of SpA., Funding: Abbvie.
- Published
- 2017
- Full Text
- View/download PDF
40. Osteonecrosis of the Femoral Head: Lipotoxicity Exacerbation in MSC and Modifications of the Bone Marrow Fluid.
- Author
-
Gillet C, Dalla Valle A, Gaspard N, Spruyt D, Vertongen P, Lechanteur J, Rigutto S, Dragan ER, Heuschling A, Gangji V, and Rasschaert J
- Subjects
- Adipogenesis drug effects, Adult, Case-Control Studies, Female, Humans, MAP Kinase Signaling System, Male, Oleic Acid blood, Palmitic Acid blood, Bone Marrow metabolism, Femur Head Necrosis blood, Mesenchymal Stem Cells drug effects, Oleic Acid toxicity, Palmitic Acid toxicity
- Abstract
Osteonecrosis of the femoral head (ON) is a multifactorial bone disease that can evolve to a progressive destruction of the hip joint. Different pathogenic processes have been proposed, among them, an increase of bone marrow (BM) fat resulting from adipocyte accumulation. Marrow adipocytes are active BM residents that influence the microenvironment by releasing cytokines, adipokines, and free fatty acids (FA). We explored the impact of palmitate (Palm) and oleate on function and survival of BM-derived mesenchymal stromal cells (MSC) of osteonecrotic patients (ONMSC) and healthy volunteers. Moreover, we analyzed the FA profile of the serum and the BM supernatant fluid (BMSF). We demonstrated that exposure to the saturated FA Palm favored MSC differentiation through the adipogenic lineage at the expense of the osteoblastic phenotype. Moreover, adipogenesis was intensified in ONMSC. The susceptibility to Palm toxicity was aggravated in ONMSC concomitantly with a greater activation of the proapoptotic extracellular signal-regulated kinase pathway. Moreover, cellular mechanisms implicated in the protection against lipotoxicity, such as stearoyl-coenzyme A desaturase 1 and carnitine palmitoyl transferase 1 expression, were dysregulated in ONMSC. Palm-induced interleukin (IL)-6 and IL-8 secretion was also exacerbated in ONMSC. Our results established that, in the serum, the FA profiles were comparable in ON and healthy subjects. However, both the concentrations and the FA composition were modified in the BMSF of ON patients, highlighting a drastic change of the BM microenvironment in ON patients. Altogether, our work suggests that marrow adipocyte enlargement could affect the process of bone remodeling and, therefore, play a role in the pathogenesis of ON., (Copyright © 2017 by the Endocrine Society.)
- Published
- 2017
- Full Text
- View/download PDF
41. Phagocyte-specific S100A8/A9 is upregulated in primary Sjögren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro.
- Author
-
Nicaise C, Weichselbaum L, Schandene L, Gangji V, Dehavay F, Bouchat J, Balau B, Vogl T, and Soyfoo MS
- Subjects
- Calgranulin A blood, Calgranulin B blood, Cytokines pharmacology, Female, Humans, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear metabolism, Male, Middle Aged, Phagocytes cytology, Phagocytes drug effects, Sjogren's Syndrome blood, Calgranulin A metabolism, Calgranulin B metabolism, Cytokines metabolism, Phagocytes metabolism, Salivary Glands metabolism, Sjogren's Syndrome metabolism, Up-Regulation
- Abstract
Objectives: To determine the role of S100A8/A9 in the pathogenesis of primary Sjögren's syndrome (pSS)., Methods: The serum levels of S100A8/A9 were determined in pSS patients and healthy controls by ELISA. The expression of S100A8/A9 in salivary glands was assessed by immunohistochemistry. The phenotype of S100A8+ and S100A9+ cells was identified using double immunofluorescence. The effects of S100A8/A9 on cytokine production by peripheral blood mononuclear cells (PBMCs) from pSS patients were determined in vitro by flow cytometry. The effects of pro-inflammatory cytokines on S100A8/A9 secretion were additionally investigated in vitro by ELISA in PBMCs from pSS patients and control subjects., Results: Serum levels of S100A8/A9 were significantly increased in pSS patients compared to healthy controls. The tissular expression of S100A8 and S100A9, identified in professional phagocytes (neutrophils, monocytes and plasmacytoid dendritic cells), was increased in the salivary glands of pSS patients and correlated with focus score. In vitro, recombinant S100A8/A9 increased the production of IL-1β, IL-6, TNF-α, IFN-γ, IL-10, IL-17A and IL-22 by PBMCs. The S100A8/A9-induced increase in TNF-α production in pSS patients was significant relative to controls. Furthermore, IL-1β, TNF-α, IL-6, and IL-17A stimulated release of S100A8/A9 from PBMCs in pSS patients., Conclusions: S100A8/A9 is increased in pSS patients contributing to the in vitro increased production of pro-inflammatory cytokines. As such, S100A8/A9 in concert with other cytokines might contribute to the pathogenesis of pSS.
- Published
- 2017
42. Biomarkers of inflammation and innate immunity in atrophic nonunion fracture.
- Author
-
de Seny D, Cobraiville G, Leprince P, Fillet M, Collin C, Mathieu M, Hauzeur JP, Gangji V, and Malaise MG
- Subjects
- Adolescent, Adult, Aged, Amino Acid Sequence, Case-Control Studies, Demography, Female, Hepcidins metabolism, Humans, Male, Middle Aged, Proteomics, Reproducibility of Results, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Two-Dimensional Difference Gel Electrophoresis, Young Adult, Biomarkers metabolism, Fractures, Ununited immunology, Fractures, Ununited pathology, Immunity, Innate, Inflammation metabolism
- Abstract
Background: Nonunion is a failure of healing following a bone fracture. Its physiopathology remains partially unclear and the discovery of new mediators could promote the understanding of bone healing., Methods: Thirty-three atrophic nonunion (NU) patients that failed to demonstrate any radiographic improvement for 6 consecutive months were recruited for providing serum samples. Thirty-five healthy volunteers (HV) served as the control group. Proteomics studies were performed using SELDI-TOF-MS and 2D-DIGE approaches, associated or not with Proteominer® preprocessing, to highlight biomarkers specific to atrophic nonunion pathology. Peak intensities were analyzed by two statistical approaches, a nonparametric Mann-Whitney U tests (univariate approach) and a machine-learning algorithm called extra-trees (multivariate approach). Validation of highlighted biomarkers was performed by alternative approaches such as microfluidic LC-MS/MS, nephelometry, western blotting or ELISA assays., Results: From the 35 HV and 33 NU crude serum samples and Proteominer® eluates, 136 spectra were collected by SELDI-TOF-MS using CM10 and IMAC-Cu(2+) ProteinChip arrays, and 665 peaks were integrated for extra-trees multivariate analysis. Accordingly, seven biomarkers and several variants were identified as potential NU biomarkers. Their levels of expression were found to be down- or up-regulated in serum of HV vs NU. These biomarkers are inter-α-trypsin inhibitor H4, hepcidin, S100A8, S100A9, glycated hemoglobin β subunit, PACAP related peptide, complement C3 α-chain. 2D-DIGE experiment allowed to detect 14 biomarkers as being down- or up-regulated in serum of HV vs NU including a cleaved fragment of apolipoprotein A-IV, apolipoprotein E, complement C3 and C6. Several biomarkers such as hepcidin, complement C6, S100A9, apolipoprotein E, complement C3 and C4 were confirmed by an alternative approach as being up-regulated in serum of NU patients compared to HV controls., Conclusion: Two proteomics approaches were used to identify new biomarkers up- or down-regulated in the nonunion pathology, which are involved in bone turn-over, inflammation, innate immunity, glycation and lipid metabolisms. High expression of hepcidin or S100A8/S100A9 by myeloid cells and the presence of advanced glycation end products and complement factors could be the result of a longstanding inflammatory process. Blocking macrophage activation and/or TLR4 receptor could accelerate healing of fractured bone in at-risk patients.
- Published
- 2016
- Full Text
- View/download PDF
43. [Camptocormia: From diagnosis to treatment].
- Author
-
Hogge M, Debrun A, and Gangji V
- Subjects
- Diagnosis, Differential, Humans, Muscle, Skeletal, Muscular Atrophy, Spinal epidemiology, Spinal Curvatures epidemiology, Walking, Muscular Atrophy, Spinal diagnosis, Muscular Atrophy, Spinal therapy, Spinal Curvatures diagnosis, Spinal Curvatures therapy
- Abstract
Camptocormia or Bent Spine Syndrome (BSS) is a symptom, often unknown, affecting elderly patients. Camptocormia is a dynamic anteflexion of the trunk occurring during physical exercises or in standing position and reducible in decubitus. It is caused by an impairment of the extensor muscles of the spinal column, either idiopathic or secondary to a muscular or a neurological disease. Its diagnosis is primarily anamnestic and clinical. The use of imaging could highlight a paraver tebral muscular fatty infi l tration with preserved volume in the case of idiopathic disorder and allows exclusion of osteoarticular pathologies. The treatment must be proposed as early as possible, before advanced adipose muscle evolution and significant anteflexion of the trunck. Symptomatic measures apply to primary and secondary forms and include physiotherapy, technical assistances to the walk and equipment by lordosis supporting corsets.
- Published
- 2016
44. Adenosine triphosphate prevents serum deprivation-induced apoptosis in human mesenchymal stem cells via activation of the MAPK signaling pathways.
- Author
-
Berlier JL, Rigutto S, Dalla Valle A, Lechanteur J, Soyfoo MS, Gangji V, and Rasschaert J
- Subjects
- Adolescent, Adult, Apoptosis drug effects, Apoptosis physiology, Caspase 3 metabolism, Caspase 7 metabolism, Cell Differentiation drug effects, Cell Differentiation physiology, Cell Proliferation drug effects, Cell Proliferation physiology, Cells, Cultured, Culture Media, Serum-Free, Humans, Mesenchymal Stem Cells enzymology, Middle Aged, Young Adult, Adenosine Triphosphate pharmacology, MAP Kinase Signaling System drug effects, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells drug effects
- Abstract
Human mesenchymal stem cells (hMSC) are multipotent cells derived from various sources including adipose and placental tissues as well as bone marrow. Owing to their regenerative and immunomodulatory properties, their use as a potential therapeutic tool is being extensively tested. However, one of the major hurdles in using cell-based therapy is the use of fetal bovine serum that can trigger immune responses, viral and prion diseases. The development of a culture medium devoid of serum while preserving cell viability is therefore a major challenge. In this study, we demonstrated that adenosine triphosphate (ATP) restrained serum deprivation-induced cell death in hMSC by preventing caspases 3/7 activation and modulating ERK1/2 and p38 MAPK signaling pathways. We also showed that serum deprivation conditions triggered dephosphorylation of the proapoptotic protein Bad leading to cell death. Adjunction of ATP restored the phosphorylation state of Bad. Furthermore, ATP significantly modulated the expression of proapoptopic and antiapoptotic genes, in favor of an antiapoptotic profile expression. Finally, we established that hMSC released a high amount of ATP in the extracellular medium when cultured in a serum-free medium. Collectively, our results demonstrate that ATP favors hMSC viability in serum deprivation conditions. Moreover, they shed light on the cardinal role of the MAPK pathways, ERK1/2 and p38 MAPK, in promoting hMSC survival., (© 2014 AlphaMed Press.)
- Published
- 2015
- Full Text
- View/download PDF
45. Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome.
- Author
-
Awada A, Nicaise C, Ena S, Schandéné L, Rasschaert J, Popescu I, Gangji V, and Soyfoo MS
- Subjects
- Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Humans, Immunohistochemistry, Interferon-gamma drug effects, Interferon-gamma metabolism, Interleukin-1 Receptor-Like 1 Protein, Interleukin-12 pharmacology, Interleukin-17 metabolism, Interleukin-23 pharmacology, Interleukin-33, Interleukins pharmacology, Killer Cells, Natural drug effects, Killer Cells, Natural metabolism, Lupus Erythematosus, Systemic metabolism, Male, Middle Aged, Natural Killer T-Cells drug effects, Natural Killer T-Cells metabolism, Sjogren's Syndrome etiology, Interleukins metabolism, Receptors, Cell Surface metabolism, Salivary Glands metabolism, Sjogren's Syndrome metabolism
- Abstract
Objectives: To investigate the role of the interleukin (IL)-33-ST2 axis in the pathophysiology of primary Sjögren's syndrome (pSS)., Methods: Serum levels of IL-33 and sST2 were determined by ELISA. The expression of IL-33 and ST2 was investigated in salivary glands (SG) by immunohistochemistry. PBMC were isolated and stimulated with IL-33, IL-12 and IL-23 and the cytokine profile response was examined by flow cytometry. Intracellular cytokine detection of IFNγ and IL-17 was performed by flow cytometry., Results: Serum IL-33 and sST2 levels were increased in pSS patients compared with controls and patients with systemic lupus erythematosus. Expression of IL-33 was upregulated in SG with Chisholm scores of 2 and 3 of pSS patients but comparable with controls for SG with Chisholm score of 4. ST2 expression in SG was downregulated in pSS patients. IL-33 at different concentrations did not increase the secretion of pro-inflammatory cytokines but acted synergistically with IL-12 and IL-23 to promote IFNγ production. NK and NKT cells were identified as main producers of IFNγ in vitro and were found in SG of pSS patients., Conclusions: IL-33 is released in pSS, and acts with IL-12 and IL-23 to favour the secretion of IFNγ by NK and NKT cells.
- Published
- 2014
- Full Text
- View/download PDF
46. Decreased pool of mesenchymal stem cells is associated with altered chemokines serum levels in atrophic nonunion fractures.
- Author
-
Mathieu M, Rigutto S, Ingels A, Spruyt D, Stricwant N, Kharroubi I, Albarani V, Jayankura M, Rasschaert J, Bastianelli E, and Gangji V
- Subjects
- Adult, Cells, Cultured, Endothelial Cells cytology, Endothelial Cells metabolism, Female, Humans, Male, Young Adult, Chemokines blood, Fractures, Ununited blood, Fractures, Ununited metabolism, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells metabolism
- Abstract
Nonunion fractures can cause severe dysfunction and are often difficult to treat mainly due to a poor understanding of their physiopathology. Although many aspects of impaired fracture healing have been extensively studied, little is known about the cellular and molecular mechanisms leading to atrophic nonunion. Therefore, the aim of the present study was to assess the pools and biological functions of bone marrow-derived mesenchymal stem cells (hMSCs) and circulating endothelial progenitor cells (EPCs) in atrophic nonunion patients compared to healthy subjects, and the systemic levels of growth factors involved in the recruitment, proliferation and differentiation of these cells. In nonunions, the pool of hMSCs was decreased and their proliferation delayed. However, once committed, hMSCs from nonunions were able to proliferate, differentiate into osteoblastic cells and mineralize in vitro as efficiently as hMSCs from healthy subjects. In parallel, we found altered serum levels of chemokines and growth factors involved in the chemotaxis and proliferation of hMSCs such as leptin, interleukin-6 (IL-6) and its soluble receptor, platelet-derived growth factor-BB (PDGF-BB), stem cell factor (SCF) and insulin-like growth factor-1 (IGF-1). Moreover, we showed that the number of EPCs and their regulating growth factors were not affected in nonunion patients. If nonunion is generally attributed to a vascular defect, our results also support a role for a systemic mesenchymal and osteogenic cell pool defect that might be related to alterations in systemic levels of factors implicated in their chemotaxis and proliferation., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
47. [Multifocal diabetic myonecrosis].
- Author
-
Uhoda R, Heuschling A, Sattari A, Hastir D, Soyfoo S, Tant L, and Gangji V
- Subjects
- Diabetic Neuropathies complications, Humans, Infarction diagnosis, Infarction etiology, Male, Middle Aged, Muscular Diseases etiology, Necrosis diagnosis, Necrosis etiology, Radiculopathy diagnosis, Radiculopathy etiology, Diabetes Complications diagnosis, Diabetic Neuropathies diagnosis, Muscular Diseases diagnosis
- Abstract
Diabetic muscle infarction is a rare and often unrecognized complication of diabetes. It typically occurs in patients with poorly controlled and multi-complicated diabetes. Typical clinical presentation is an indurate muscle pain, mainly localized in the lower limb with an acute onset. In most cases, diabetes myonecrosis is focal and sometimes can be recurrent. Diagnosis is clinical but can used magnetic resonance imaging (MRI). Muscle biopsy is sometimes necessary in cases of doubt or to confirm the imaging diagnosis. Elevation of muscle enzymes (CPK) is present in half of cases. Management is conservative and the clinical and imaging evolution is usually favourable. We report the case of a patient presenting a subacute hyperalgesic lomboradiculopathy.
- Published
- 2012
48. Diffuse Muscular Pain, Skin Tightening, and Nodular Regenerative Hyperplasia Revealing Paraneoplastic Amyopathic Dermatomyositis due to Testicular Cancer.
- Author
-
Norrenberg S, Gangji V, Del Marmol V, and Soyfoo MS
- Abstract
Paraneoplastic dermatomyositis (DM) associated with testicular cancer is extremely rare. We report the case of a patient with skin tightening, polymyalgia, hypereosinophilia, and nodular regenerative hyperplasia revealing seminoma and associated paraneoplastic DM.
- Published
- 2012
- Full Text
- View/download PDF
49. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study.
- Author
-
Gangji V, De Maertelaer V, and Hauzeur JP
- Subjects
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Prospective Studies, Transplantation, Autologous, Bone Marrow Transplantation, Femur Head pathology, Osteonecrosis surgery
- Abstract
Objective: To determine the efficacy of bone marrow cell implantation into the necrotic lesion of the femoral head on clinical symptoms and the progression of osteonecrosis of the femoral head in comparison with core decompression., Methods: We studied nineteen patients and twenty four hips with early stage osteonecrosis of the femoral head. The hips were allocated to either core decompression only or core decompression and implantation of bone marrow cells. Both patients and assessors were blind with respect to treatment group assignment. The primary outcomes were clinical symptoms and disease progression., Results: Bone marrow implantation afforded a significant reduction in pain and in joint symptoms and reduced the incidence of fractural stages. At 60 months, eight of the eleven hips in the control group had deteriorated to the fractural stage whereas only three of the thirteen hips in the bone marrow graft group had progressed to that stage. Survival analysis showed a significant difference in the time to failure between the two groups at 60 months. Patients had only minor side-effects after the treatments., Conclusions: This long term follow-up study confirmed that implantation of autologous bone marrow cells in the necrotic lesion might be an effective treatment for patients with early stages of osteonecrosis of the femoral head., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
50. [Treatment of bone diseases with cell therapy].
- Author
-
Gangji V
- Subjects
- Adult, Humans, Bone Marrow Transplantation, Cell- and Tissue-Based Therapy, Femur Head Necrosis therapy, Mesenchymal Stem Cell Transplantation
- Abstract
Osteonecrosis of the femoral head is a rare disease that affects young patients and is characterized by the occurrence of a necrotic lesion in the femoral head, loss of mechanical resistance of dead bone and collapse of the femoral head. Patients complain of hip pain and loss of function that could lead to total hip replacement. So far, osteonecrosis was considered as a vascular disease due to vascular section or compression leading to bone necrosis. We studied the physiopathology of the osteonecrosis considering it as a bone disease. We demonstrated as well as other teams that the number of mesenchymal stem cells, precursors of bone cells and osteoblastic cells, were reduced in patients with osteonecrosis. We initiated a controlled double blind trial to study the efficacy of stem cells implantation--obtained from concentrated bone marrow--in the osteonecrosis zone. This study showed that bone marrow implantation could delay disease progression to the fractural stage and improve hip pain and joint symptoms. We then tried to improve this treatment by developing a bone cell therapy product formed of osteoblastic cells. A novel cell therapy product formed ofosteoblastic cells, PREOB was developed. PREOB was tested in a randomized, controlled phase II trial in osteonecrosis of the femoral head and showed its superiority compared to concentrated bone marrow. Today, this cellular therapy product is developed by Bone Therapeutics, a spin-offcompany of the "Université libre de Bruxelles". Other bone diseases are characterized by reduced activities of stem cells that are unable to meet the need of bone remodelling due to a non-union fracture, for example. Clinical studies also showed that concentrated bone marrow could be implanted into the non-union. However, its efficacy was dependent on the number of implanted stem cells. The cellular therapy product is currently tested in a phase I trial with promising preliminary results. Cellular therapy for bone diseases is a novel therapeutic approach that evolves from stem cells to the use of the differentiated cells of interest.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.